1. Clinical Overview
A fixed-dose combination (FDC) of two centrally acting agents with complementary mechanisms for the symptomatic treatment of moderate to severe Alzheimer's disease (AD). Donepezil is a reversible, non-competitive acetylcholinesterase inhibitor (AChEI) that increases acetylcholine levels in the synaptic cleft. Memantine is a low-to-moderate affinity, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that modulates glutamate activity. This combination addresses both cholinergic deficit and glutamatergic excitotoxicity, providing a dual neurochemical approach to stabilize cognitive and functional decline.
| Onset | Duration | Bioavailability |
|---|---|---|
| Cognitive effects may be observed within 4-8 weeks of continuous therapy, though peak clinical benefit may take up to 12 weeks. | Pharmacodynamic effects last 24 hours, supporting once-daily dosing. The therapeutic benefits on cognition and function are sustained with continued treatment. | Donepezil: ~100%. Memantine: ~100%. |
2. Mechanism of Action
The combination exerts a dual neurochemical action. Donepezil inhibits acetylcholinesterase in the brain, increasing the concentration of acetylcholine, a neurotransmitter crucial for memory, learning, and attention, which is deficient in AD. Memantine blocks NMDA receptors, preventing excessive calcium influx into neurons caused by pathological, tonic release of glutamate. This mitigates excitotoxicity, neuronal dysfunction, and apoptosis. Together, they modulate cholinergic and glutamatergic pathways to stabilize synaptic transmission and cognitive function.
3. Indications & Uses
- Symptomatic treatment of moderate to severe Alzheimer's disease
4. Dosage & Administration
Adult Dosage: For patients already stabilized on donepezil 10 mg and memantine 10 mg individually: One tablet (Donepezil 10mg + Memantine 10mg) orally once daily, preferably at bedtime. For memantine-naïve patients: Initiate memantine monotherapy (5 mg OD, titrate to 10 mg BD over 4 weeks) before switching to this FDC.
Administration: Administer orally, with or without food. Swallow whole with a glass of water. Preferably taken at bedtime to minimize potential cholinergic side effects like nausea and dizziness. Do not crush or chew.
5. Side Effects
Common side effects may include:
- Nausea
- Diarrhea
- Headache
- Dizziness
- Constipation
- Vomiting
- Fatigue
- Anorexia
- Pain in extremities
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Anticholinergic agents (e.g., Atropine, Oxybutynin, Tricyclic Antidepressants) | May antagonize the therapeutic effect of donepezil. | Major |
| Cholinergic agonists (e.g., Bethanechol, Pilocarpine) | Additive cholinergic effects, increased risk of side effects. | Moderate |
| Beta-blockers, Digoxin, Non-DHP CCBs (e.g., Diltiazem, Verapamil) | Increased risk of bradycardia and heart block with donepezil. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of gastrointestinal bleeding with donepezil. | Moderate |
| Carbamazepine, Phenytoin, Phenobarbital, Rifampicin | Inducers of CYP3A4/2D6 may decrease plasma levels of donepezil. | Moderate |
| Ketoconazole, Quinidine, Paroxetine | Inhibitors of CYP3A4/2D6 may increase plasma levels of donepezil. | Moderate |
| Drugs that alkalinize urine (e.g., Sodium Bicarbonate, Acetazolamide) | May decrease renal excretion of memantine, increasing its levels. | Moderate |
| Other NMDA antagonists (e.g., Amantadine, Ketamine, Dextromethorphan) | Additive CNS effects; increased risk of dizziness, confusion, psychosis. | Major |
7. Patient Counselling
- DO take the medication exactly as prescribed, usually once daily at bedtime.
- DO inform all your doctors and dentists you are taking this medicine.
- DO keep a regular follow-up schedule with your neurologist/psychiatrist.
- DO ensure adequate fluid intake unless contraindicated.
- DO NOT stop taking the medicine suddenly without consulting your doctor.
- DO NOT double the dose if you miss one. Skip it and take the next dose at the usual time.
- DO NOT take over-the-counter cold, cough, or allergy medicines without checking with your doctor or pharmacist.
8. Toxicology & Storage
Overdose: Cholinergic crisis (severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, convulsions, muscle weakness - possibly leading to death) from donepezil. Memantine overdose can cause restlessness, psychosis, visual hallucinations, somnolence, stupor, loss of consciousness.
Storage: Store at room temperature (15-30°C). Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children. Do not use after the expiry date printed on the pack.